Baidu
map

Medicine:年轻缺血性卒中和先前存在精神障碍

2015-09-26 phylis 译 MedSci原创

先前研究表明精神障碍比如:严重抑郁症,双相障碍以及酒精使用障碍与缺血性卒中的发生相关。然而,在精神障碍和年轻患者卒中之间的关系研究的较少。应用台湾国家健康保险数据库,招募了1998年到2011年间,18到45岁缺血性卒中患者,8252名年龄和性别相匹配的对照组。确定先前存在精神障碍的受试者。校正先前存在生理疾病和人口学数据。缺血性卒中的患者先前存在精神障碍的风险较高,包括双相障碍(OR: 2.23

先前的研究表明精神障碍比如:严重抑郁症、双相障碍以及酒精使用障碍与缺血性卒中的发生相关。然而,在精神障碍和年轻患者卒中之间的关系研究的较少。

应用台湾国家健康保险数据库,招募了1998年到2011年间,18到45岁缺血性卒中患者,8252名年龄和性别相匹配的对照组。确定先前存在精神障碍的受试者。校正先前存在生理疾病和人口学数据。

缺血性卒中的患者先前存在精神障碍的风险较高,包括双相障碍(OR: 2.23, 95% CI: 1.06∼4.67),抑郁症(OR: 2.15, 95% CI: 1.62∼2.86),焦虑障碍(OR: 2.63, 95% CI: 1.87∼3.69),酒精使用障碍(OR: 2.86, 95% CI: 1.79∼4.57)。年轻缺血性卒中(年龄大于30岁)与先前存在抑郁症(OR: 1.49, 95% CI: 1.05∼2.11)、焦虑障碍(OR: 1.99, 95% CI: 1.33∼2.97)以及酒精使用障碍(OR: 2.54, 95% CI: 1.55∼4.14)风险相关。


非常年轻的卒中患者(年龄小于30岁)仅与先前存在抑郁症相关(OR: 4.15, 95% CI: 1.47∼11.72)。

校正人口学数据以及卒中相关医疗共发病后,缺血性卒中年龄低于45岁的患者先前存在双相障碍
抑郁症、焦虑障碍以及酒精使用障碍风险较高。

原文出处:

Chiu YC, Bai YM, Su TP, et al. Ischemic Stroke in Young Adults and Preexisting Psychiatric Disorders: A Nationwide Case-Control Study. Medicine (Baltimore).Sep 9, 2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1806030, encodeId=793f1806030cf, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 06 15:50:00 CST 2015, time=2015-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892679, encodeId=845a18926e9d1, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 17 17:50:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858626, encodeId=9f7b185862679, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Feb 22 14:50:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773504, encodeId=09b21e73504b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 03 09:50:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577436, encodeId=0b1515e743678, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Sep 28 11:50:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606626, encodeId=bdd01606626af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 28 11:50:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1806030, encodeId=793f1806030cf, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 06 15:50:00 CST 2015, time=2015-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892679, encodeId=845a18926e9d1, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 17 17:50:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858626, encodeId=9f7b185862679, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Feb 22 14:50:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773504, encodeId=09b21e73504b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 03 09:50:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577436, encodeId=0b1515e743678, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Sep 28 11:50:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606626, encodeId=bdd01606626af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 28 11:50:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1806030, encodeId=793f1806030cf, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 06 15:50:00 CST 2015, time=2015-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892679, encodeId=845a18926e9d1, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 17 17:50:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858626, encodeId=9f7b185862679, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Feb 22 14:50:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773504, encodeId=09b21e73504b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 03 09:50:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577436, encodeId=0b1515e743678, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Sep 28 11:50:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606626, encodeId=bdd01606626af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 28 11:50:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
    2016-02-22 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1806030, encodeId=793f1806030cf, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 06 15:50:00 CST 2015, time=2015-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892679, encodeId=845a18926e9d1, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 17 17:50:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858626, encodeId=9f7b185862679, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Feb 22 14:50:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773504, encodeId=09b21e73504b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 03 09:50:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577436, encodeId=0b1515e743678, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Sep 28 11:50:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606626, encodeId=bdd01606626af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 28 11:50:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
    2015-10-03 kalseyzl
  5. [GetPortalCommentsPageByObjectIdResponse(id=1806030, encodeId=793f1806030cf, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 06 15:50:00 CST 2015, time=2015-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892679, encodeId=845a18926e9d1, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 17 17:50:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858626, encodeId=9f7b185862679, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Feb 22 14:50:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773504, encodeId=09b21e73504b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 03 09:50:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577436, encodeId=0b1515e743678, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Sep 28 11:50:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606626, encodeId=bdd01606626af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 28 11:50:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1806030, encodeId=793f1806030cf, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 06 15:50:00 CST 2015, time=2015-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892679, encodeId=845a18926e9d1, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 17 17:50:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858626, encodeId=9f7b185862679, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Feb 22 14:50:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773504, encodeId=09b21e73504b7, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 03 09:50:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577436, encodeId=0b1515e743678, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Sep 28 11:50:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606626, encodeId=bdd01606626af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 28 11:50:00 CST 2015, time=2015-09-28, status=1, ipAttribution=)]

相关资讯

Geriatr Gerontol Int:卒中前痴呆对其缺血性卒中的影响

目的:这篇研究的主要目的是确定卒中前痴呆(PSD)是否影响老年缺血性卒中患者的短期功能预后。方法:对老年缺血性卒中患者进行回顾性病例对照研究。应用功能独立测量量表(FIM)对患者入院和出院时进行功能预后评估。应用t检验,卡方检验,多次线性回归以及logistics回归分析数据。结果:急性缺血性卒中患者919名,其中11.5%诊断为PSD。与非PSD患者相比,PSD患者,存活时间较短,女性患者比例较

Atherosclerosis:空腹及餐后甘油三酯和颈动脉内膜厚度的关系

背景:颈总动脉内膜厚度(CCA-IMT)是动脉粥样硬化的一种检测指标。甘油三酯在CCA-IMT中的作用尚有争议。研究人员旨在确定是否空腹及餐后甘油三酯与CCA-IMT相关。 方法:招募2009年1月到2014年1月期间参与柏林“Cream和Sugar”研究中的急性缺血性卒中患者,并对其进行颈动脉超声检测的患者。第一次缺血性卒中后,对患者进行3-7天口服糖和甘油三酯耐受实验。根据甘油三酯的代谢情况,

Int J Stroke:急性缺血性卒中药物治疗还是血管内血栓切除?

大血管梗塞的急性缺血性卒中患者行静脉溶栓治疗,血管再通效果较差。最近的研究表明血管内治疗,患者血管再通及预后较单纯药物治疗好。系统性综述和meta-分析调查血管内血栓切除术的相关随机对照试验优势,并且至少有25%的患者应用血栓切除设备进行急性缺血性卒中患者治疗,并且这些患者未进行药物治疗。对血管内血栓切除和药物治疗急性缺血性卒中患者的疗效进行系统性综述和meta-分析。我们研究选取了437个研究,

BMJ Open:抗癫痫药与缺血性卒中和心肌梗死发生的关系

目的:肝酶诱导的抗癫痫药物(AEDs)通过诱导细胞色素P450增加血浆中的脂质及其他动脉粥样硬化标志物,因此可能会增加血管事件的发生。研究人员根据AED代谢的酶特性旨在评估其对缺血性卒中和心肌梗死(MI)发生的风险。设计:病例对照分析的群体队列研究。英国临床实践研究数据链中的650个普通医生的医业。受试者:招募1990年1月到2013年4月间252407名应用AED的患者,患者年龄在18岁以上。每

J Am Heart Assoc: 预测缺血性卒中后的再入院模型

背景:减少患者再入院是卒中护理的主要改革部分。当前的再入院预测模型准确性较差,并且仅局限于急性入院的数据。研究人员假设基于全国范围内的急性期后护理数据库的患者因素可能改善预测模型。方法:应用2008年的国际疾病分类(第九版)确诊并筛选出大于65岁缺血性卒中患者。应最小数据集(MDS)对患者急性期后护理进行综合评估。应用logistic回归建立风险校正再入院模型。协变量为MDS变量。结果:在3917

Clin Chim Acta:血管反应素-1对急性缺血性卒中患者预后的预测价值

血管反应素-1是血管再生的有效调节剂。脑出血的大鼠模型中脑中血管反应素-1的表达增加。当前的研究主要是确定血浆中血管反应素-1浓度的变化以及评估血浆血管反应素-1浓度对缺血性卒中患者长期的死亡率和功能预后的预测价值。这篇研究包括192名患者,150名健康者作为对照。应用酶联免疫吸附试验测定血浆中血管反应素-1的浓度。不利预后以mRS分数大于3为标准。应用多变量分析血浆血管反应素-1浓度和6个月临床

Baidu
map
Baidu
map
Baidu
map